{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:12:35Z","timestamp":1761293555105},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T00:00:00Z","timestamp":1491782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T00:00:00Z","timestamp":1491782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s12029-017-9946-5","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T03:15:36Z","timestamp":1491794136000},"page":"135-147","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed"],"prefix":"10.1007","volume":"48","author":[{"given":"Jorge","family":"Hernando-Cubero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Matos-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Alonso-Ordu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,10]]},"reference":[{"issue":"4","key":"9946_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","volume":"46","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765\u201381.","journal-title":"Eur J Cancer"},{"key":"9946_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-540-46091-6_8","volume":"176","author":"J Stoehlmacher","year":"2007","unstructured":"Stoehlmacher J. Prediction of efficacy and side effects of chemotherapy in colorectal cancer. Recent Results Cancer Res. 2007;176:81\u20138.","journal-title":"Recent Results Cancer Res"},{"issue":"9","key":"9946_CR3","first-page":"1211","volume":"16","author":"R Di Francia","year":"2012","unstructured":"Di Francia R, Siesto RS, Valente D, et al. Pharmacogenomics panel test for prevention toxicity in patient who receive fluoropirmidine\/oxaliplatin-based therapy. Eur Rev Pharmacol Sci. 2012;16(9):1211\u20137.","journal-title":"Eur Rev Pharmacol Sci"},{"issue":"3","key":"9946_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.clinthera.2010.03.012","volume":"32","author":"J Tol","year":"2010","unstructured":"Tol J, Punt CJ. Monoclonal antiboides in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32(3):437\u201353.","journal-title":"Clin Ther"},{"key":"9946_CR5","first-page":"282","volume":"11","author":"PM Wilson","year":"2014","unstructured":"Wilson PM, Danenberg PV, Johnston PG, et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nature Reviews. 2014;11:282\u201398.","journal-title":"Nature Reviews"},{"key":"9946_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-1-4684-1248-2_15","volume":"195B","author":"M Goulian","year":"1986","unstructured":"Goulian M, Bleile BM, Dickey LM, et al. Mechanisms of thymineless death. Adv Exp Med Biol. 1986;195B:89\u201395.","journal-title":"Adv Exp Med Biol"},{"key":"9946_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0092-8674(78)90330-6","volume":"13","author":"K Brynolf","year":"1978","unstructured":"Brynolf K, Eliasson R, Reichard P. Formation of Okazaki fragments in polyoma DNA synthesis caused by misincorporation of uracil. Cell. 1978;13:573\u201380.","journal-title":"Cell"},{"key":"9946_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/179663a0","volume":"179","author":"C Heidelberg","year":"1957","unstructured":"Heidelberg C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663\u20136.","journal-title":"Nature"},{"key":"9946_CR9","first-page":"168","volume":"30","author":"JJ Jaffe","year":"1957","unstructured":"Jaffe JJ, Handschumacher RE, Welch AD. Studies of the carcinostatic activity in mice of 6-azauracil riboside (azauridine), incomparison with that of 6-azauracil. Yale J Biol Med. 1957;30:168\u201375.","journal-title":"Yale J Biol Med"},{"issue":"10","key":"9946_CR10","first-page":"72","volume":"27","author":"A Sobrero","year":"2000","unstructured":"Sobrero A, Guglieimi A, Grossi F, et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal c\u00e1ncer chemotherapy. Semin Oncol. 2000;27(10):72\u20137.","journal-title":"Semin Oncol"},{"issue":"1","key":"9946_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1200\/JCO.1997.15.1.368","volume":"15","author":"AF Sobrero","year":"1997","unstructured":"Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer\u2014a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 1997;15(1):368\u201381.","journal-title":"J Clin Oncol"},{"key":"9946_CR12","unstructured":"Houghton JA, Maroda SJ, Phillips JO, Houghton PJ. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res. 1981;41:144\u201349"},{"issue":"18","key":"9946_CR13","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2004.03.104","volume":"22","author":"The Meta-Analysis Group in Cancer","year":"2004","unstructured":"The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Jour Clin Oncol. 2004;22(18):3766\u201375.","journal-title":"Jour Clin Oncol"},{"issue":"4","key":"9946_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/07357909809039773","volume":"16","author":"B Ardalan","year":"1998","unstructured":"Ardalan B, Luis R, Jaime M, et al. Biomodulation of fluorouracil in colorectal c\u00e1ncer. Cancer Investig. 1998;16(4):237\u201351.","journal-title":"Cancer Investig"},{"key":"9946_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s002800050835","volume":"42","author":"S Mullany","year":"1998","unstructured":"Mullany S, Svingen PA, Kaufmann SH, et al. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol. 1998;42:391\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"9946_CR16","first-page":"3717","volume":"60","author":"S Cao","year":"2000","unstructured":"Cao S, Rustum Y. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res. 2000;60:3717.","journal-title":"Cancer Res"},{"key":"9946_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.bjc.6600185","volume":"86","author":"JL Fischel","year":"2002","unstructured":"Fischel JL, Formento P, Ciccolini J, et al. Mpact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracelular determinants of drug activity. Br J Cancer. 2002;86:1162\u20138.","journal-title":"Br J Cancer"},{"issue":"1","key":"9946_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3747\/co.v18i1.708","volume":"18","author":"T Alcindor","year":"2011","unstructured":"Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18(1):18\u201325.","journal-title":"Curr Oncol"},{"key":"9946_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1158\/1078-0432.CCR-07-1225","volume":"14","author":"JL Yen-Revollo","year":"2008","unstructured":"Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res. 2008;14:8\u201313.","journal-title":"Clin Cancer Res"},{"key":"9946_CR20","first-page":"2406","volume":"39","author":"JA Houghton","year":"1979","unstructured":"Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2-deoxyuridine. Cancer Res. 1979;39:2406\u201313.","journal-title":"Cancer Res"},{"issue":"4","key":"9946_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","volume":"58","author":"SA Jensen","year":"2006","unstructured":"Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"9946_CR22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","volume":"39","author":"A Polk","year":"2013","unstructured":"Polk A, Vaage-Nilsen M, Vistinsen K, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974\u201384.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"9946_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3816\/CCC.2006.n.046","volume":"6","author":"CJ Twelves","year":"2006","unstructured":"Twelves CJ. Xeloda in adjuvant colon cancer therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer. 2006;6(4):278\u201387.","journal-title":"Clin Colorectal Cancer"},{"key":"9946_CR24","unstructured":"Hodi FS, Catalano P, Macdonald JS, et al. Age as a factor influencing the toxicity of adjuvant chemotherapy for colorectal c\u00e1ncer. Abstract presented at 2nd International Conference on Gastrointestinal Oncology, Cologne, Germany, 1994."},{"issue":"1","key":"9946_CR25","first-page":"23","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C. Capecitabine: a review. ClinTher. 2005;27(1):23\u201344.","journal-title":"ClinTher"},{"key":"9946_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s002800050043","volume":"45","author":"J Schuller","year":"2000","unstructured":"Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumour following oral administation to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"9946_CR27","first-page":"332","volume":"176","author":"SA Hiller","year":"1967","unstructured":"Hiller SA, Zhuk RA, Lidak MY. Analogs of pyrimidine nucleosides. Dokl Adad Nauk. 1967;176:332\u20135.","journal-title":"Dokl Adad Nauk"},{"issue":"8","key":"9946_CR28","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1200\/JCO.1998.16.8.2877","volume":"16","author":"H Takiuchi","year":"1998","unstructured":"Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998;16(8):2877\u201385.","journal-title":"J Clin Oncol"},{"key":"9946_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1517\/13543780902729412","volume":"18","author":"MW Saif","year":"2009","unstructured":"Saif MW, Syrigos KN, Katirzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18:335\u201348.","journal-title":"Expert Opin Investig Drugs"},{"key":"9946_CR30","first-page":"1705","volume":"21","author":"T Kato","year":"2001","unstructured":"Kato T, Shimamoto Y, Uchida J, et al. Possible regulation of 5-fluorouracil-induced neuro and oral toxicities by two biochemical modulators consisting of S-1 a new oral formulation of 5-fluorouracil. Anticancer Res. 2001;21:1705\u201312.","journal-title":"Anticancer Res"},{"key":"9946_CR31","unstructured":"Heidelberger C, Boohar J, Kampschroer xx, et al. Fluorinated pyrimidines. In vivo metabolism of 5-trifluoromethyluracil-2-C-14 nd 5-trifluoromethyl-2\u2032-deoxyuridine-2-C-14. Cancer Res. 1965;25:377\u2013381"},{"key":"9946_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1349-7006.2007.00477.x","volume":"98","author":"O Temmink","year":"2007","unstructured":"Temmink O, Emura T, De Bruin M, et al. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci. 2007;98:779\u201389.","journal-title":"Cancer Sci"},{"key":"9946_CR33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/etm.2011.244","volume":"2","author":"N Suzuki","year":"2011","unstructured":"Suzuki N, Nakagawa F, Nukatsuka M, et al. Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther MEd. 2011;2:393\u20137.","journal-title":"Exp Ther MEd"},{"key":"9946_CR34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/15257770.2014.894197","volume":"33","author":"G Peters","year":"2014","unstructured":"Peters G. Novel developments in the use of antimetabolites. Nucleosides Nucleotides Nucleic Acids. 2014;33:358\u201374.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"9946_CR35","first-page":"545","volume":"13","author":"T Emure","year":"2004","unstructured":"Emure T, Murakami Y, Nakagawa F, et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med. 2004;13:545\u20139.","journal-title":"Int J Mol Med"},{"key":"9946_CR36","first-page":"247","volume":"32","author":"D Dexter","year":"1972","unstructured":"Dexter D, Wolberg W, Ansfield F, et al. The clinical pharmacology of 5-trifluoromethyl-2\u2032-deoxyuridine. Cancer Res. 1972;32:247\u201353.","journal-title":"Cancer Res"},{"key":"9946_CR37","first-page":"449","volume":"27","author":"T Emura","year":"2005","unstructured":"Emura T, Suzuki N, Fujioka A, et al. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thmidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol. 2005;27:449\u201355.","journal-title":"Int J Oncol"},{"key":"9946_CR38","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319.","journal-title":"N Engl J Med"},{"key":"9946_CR39","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/0959-8049(95)00326-E","volume":"31A","author":"L Leichman","year":"1995","unstructured":"Leichman L, Lenz HJ, Leichman CG, et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer. 1995;31A:1306\u201310.","journal-title":"Eur J Cancer"},{"key":"9946_CR40","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1002\/ijc.23822","volume":"123","author":"LX Qui","year":"2008","unstructured":"Qui LX, Tang QY, Bai JL, et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer. 2008;123:2384\u20139.","journal-title":"Int J Cancer"},{"key":"9946_CR41","first-page":"2644","volume":"62","author":"DB Longley","year":"2002","unstructured":"Longley DB, Boyer J, Allen WL, et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res. 2002;62:2644\u20139.","journal-title":"Cancer Res"},{"key":"9946_CR42","first-page":"2898","volume":"63","author":"MV Mandola","year":"2003","unstructured":"Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5\u2032 tandem repeat polymorphism of the thymidiylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003;63:2898\u2013904.","journal-title":"Cancer Res"},{"key":"9946_CR43","first-page":"1381","volume":"9","author":"CM Ulrich","year":"2000","unstructured":"Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epideimol Biomarkers Prev. 2000;9:1381\u20135.","journal-title":"Cancer Epideimol Biomarkers Prev"},{"key":"9946_CR44","first-page":"4705","volume":"6","author":"AB Van Kuilenburg","year":"2000","unstructured":"Van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6:4705\u201312.","journal-title":"Clin Cancer Res"},{"key":"9946_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/CAD.0b013e3283293fd4","volume":"20","author":"G Aprile","year":"2009","unstructured":"Aprile G, Mazzer M, Moroso S, et al. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anti-Cancer Drugs. 2009;20:217\u201329.","journal-title":"Anti-Cancer Drugs"},{"issue":"10","key":"9946_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078053","volume":"8","author":"BA Jennings","year":"2013","unstructured":"Jennings BA, Loke YK, Skinner J, et al. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One. 2013;8(10):e78053.","journal-title":"PLoS One"},{"key":"9946_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/pgs.10.188","volume":"12","author":"FA Muhale","year":"2011","unstructured":"Muhale FA, Wetmore BA, Thomas RS, et al. Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics. 2011;12:341\u201350.","journal-title":"Pharmacogenomics"},{"key":"9946_CR48","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/jnci\/djh015","volume":"96","author":"KJ Sohn","year":"2004","unstructured":"Sohn KJ, Croxford R, Yates Z, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst. 2004;96:134\u201344.","journal-title":"J Natl Cancer Inst"},{"key":"9946_CR49","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2007.11.4710","volume":"25","author":"W Zhang","year":"2007","unstructured":"Zhang W, Press OA, Haiman CA, et al. Association of mehylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastastic colon cancer. J Clin Oncol. 2007;25:3726\u201331.","journal-title":"J Clin Oncol"},{"issue":"29","key":"9946_CR50","doi-asserted-by":"publisher","first-page":"9775","DOI":"10.3748\/wjg.v20.i29.9775","volume":"20","author":"M Panczyk","year":"2014","unstructured":"Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20(29):9775\u2013827.","journal-title":"World J Gastroenterol"},{"key":"9946_CR51","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/oxfordjournals.annonc.a059353","volume":"6","author":"AL Jackman","year":"1995","unstructured":"Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol. 1995;6:871\u201381.","journal-title":"Ann Oncol"},{"key":"9946_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4899-2638-8_4","volume":"309A","author":"AL Jackman","year":"1991","unstructured":"Jackman AL, Jodrell DI, Gibson W, et al. ICI D1694, an inhibitor of thymidylate synthase for clinical sutdy. AdvExp Med Biol. 1991;309A:19\u201323.","journal-title":"AdvExp Med Biol"},{"key":"9946_CR53","first-page":"265","volume":"339","author":"AL Jackman","year":"1993","unstructured":"Jackman AL, Gibson W, Brown M, et al. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. SfbRcpMrfNiol. 1993;339:265\u201376.","journal-title":"SfbRcpMrfNiol"},{"key":"9946_CR54","doi-asserted-by":"crossref","unstructured":"Price T, Wilson K, Simes RJ, et al. Final results of Australasian Gastro-Intestinal Trials Group (AGITG) ARCTIC Study. An international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines (FP). Paper presented at Annals Oncology, ESMO; Vienna, Austria; 2012","DOI":"10.1016\/S0923-7534(20)33085-4"},{"issue":"10","key":"9946_CR55","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ejca.2013.03.004","volume":"49","author":"C Kelly","year":"2013","unstructured":"Kelly C, Bhuva N, Harrison M, et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer. 2013;49(10):2303\u201310.","journal-title":"Eur J Cancer"},{"key":"9946_CR56","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1200\/JCO.1991.9.5.827","volume":"9","author":"JA Wils","year":"1991","unstructured":"Wils JA, Klein HO, Wagener DJT, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin\u2014a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991;9:827\u201331.","journal-title":"J Clin Oncol"},{"key":"9946_CR57","first-page":"2425","volume":"26","author":"MG Zampino","year":"2006","unstructured":"Zampino MG, Lorizzo K, Rocca A, et al. Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer. Anticancer Res. 2006;26:2425\u20138.","journal-title":"Anticancer Res"},{"issue":"13","key":"9946_CR58","first-page":"56","volume":"18","author":"C Louvet","year":"2004","unstructured":"Louvet C, de Gramont A. Pemetrexed in advanced colorectal cancer. Oncology (Williston Park). 2004;18(13):56\u201362.","journal-title":"Oncology (Williston Park)"},{"key":"9946_CR59","unstructured":"ClinicalTrials.gov NCT02588781"},{"issue":"12","key":"9946_CR60","first-page":"1122","volume":"25","author":"C Cao","year":"2015","unstructured":"Cao C, Kuang M, Xu W, et al. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer. Jpn Clin Oncol. 2015;25(12):1122\u201330.","journal-title":"Jpn Clin Oncol"},{"key":"9946_CR61","doi-asserted-by":"crossref","unstructured":"Shoji H, Morizane C, Sakamoto Y, et al. Phase I trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract c\u00e1ncer. Jpnj J ClinOncol. 2015; Epub ahead of print","DOI":"10.1093\/jjco\/hyv179"},{"key":"9946_CR62","doi-asserted-by":"crossref","unstructured":"Ueno M, Okusaka T, Omuro Y, et al. A randomized phase II study plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Ann Oncol. 2015; Epub ahead of print","DOI":"10.1093\/annonc\/mdv603"},{"key":"9946_CR63","first-page":"193","volume":"4","author":"M Kobayakawa","year":"2011","unstructured":"Kobayakawa M, Kojima Y. Tegafur\/gimeracil\/oteracil (S-a) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. OncoThargets. 2011;4:193\u2013201.","journal-title":"OncoThargets"},{"key":"9946_CR64","doi-asserted-by":"crossref","unstructured":"Yano W, Yokogaway T, Fukuoka M, et al. In vitro characterization of a novel dUTPase inhibitor, TAS-114 as a fluoropyrimidine enhancer. 24th EORTC-NCI-AACR symposium 2012; Abstract 67","DOI":"10.1016\/S0959-8049(12)71865-8"},{"key":"9946_CR65","unstructured":"ClinicalTrials.gov NCT01610479"},{"key":"9946_CR66","unstructured":"ClinicalTrials.gov NCT01489865"},{"key":"9946_CR67","unstructured":"ClinicalTrials.gov NCT01589419"},{"issue":"24","key":"9946_CR68","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1001\/jama.1988.03720240033031","volume":"259","author":"M Buyse","year":"1988","unstructured":"Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don\u2019t know. JAMA. 1988;259(24):3571\u20138.","journal-title":"JAMA"},{"issue":"6","key":"9946_CR69","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJM199002083220602","volume":"322","author":"CG Moertel","year":"1990","unstructured":"Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy colon carcinoma. N Engl J Med. 1990;322(6):352\u20138.","journal-title":"N Engl J Med"},{"key":"9946_CR70","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa010957","volume":"345","author":"DJ Sargent","year":"2001","unstructured":"Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091\u20137.","journal-title":"N Engl J Med"},{"key":"9946_CR71","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","volume":"370","author":"QUASAR Collaborative Group","year":"2007","unstructured":"QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020\u20139.","journal-title":"Lancet"},{"key":"9946_CR72","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343\u201351.","journal-title":"N Engl J Med"},{"key":"9946_CR73","unstructured":"Andre T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC Study. J Clin Oncol. 2015. ePub ahead to print."},{"key":"9946_CR74","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2005.04.7498","volume":"24","author":"BC Lembersky","year":"2006","unstructured":"Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24:2059\u201364.","journal-title":"J Clin Oncol"},{"key":"9946_CR75","doi-asserted-by":"crossref","unstructured":"Kuebler JP, Wieand HS, O\u2019Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP-C07. J Clin Oncol. 2007;25:2198\u20132204","DOI":"10.1200\/JCO.2006.08.2974"},{"key":"9946_CR76","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers G, MJ O\u2019C, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768\u201374.","journal-title":"J Clin Oncol"},{"key":"9946_CR77","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696\u2013704.","journal-title":"N Engl J Med"},{"key":"9946_CR78","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/annonc\/mdr366","volume":"23","author":"C Twelves","year":"2012","unstructured":"Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23:1190\u20137.","journal-title":"Ann Oncol"},{"key":"9946_CR79","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","volume":"29","author":"DG Haller","year":"2011","unstructured":"Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465\u201371.","journal-title":"J Clin Oncol"},{"key":"9946_CR80","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","volume":"25","author":"HJ Schmoll","year":"2007","unstructured":"Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. J Clin Oncol. 2007;25:102\u20139.","journal-title":"J Clin Oncol"},{"key":"9946_CR81","doi-asserted-by":"crossref","unstructured":"Schmoll HJ, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015; ePub ahead to print","DOI":"10.1200\/JCO.2015.60.9107"},{"issue":"15","key":"9946_CR82","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.ejca.2008.07.002","volume":"44","author":"I Popov","year":"2008","unstructured":"Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer. 2008;44(15):2201\u201311.","journal-title":"Eur J Cancer"},{"key":"9946_CR83","first-page":"1","volume":"00","author":"M Yoshida","year":"2014","unstructured":"Yoshida M, Ishiguro M, Ikejiri K, et al. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol. 2014;00:1\u20137.","journal-title":"Ann Oncol"},{"key":"9946_CR84","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","volume":"16","author":"The Meta-analysis Group in Cancer","year":"1998","unstructured":"The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301\u20138.","journal-title":"J Clin Oncol"},{"key":"9946_CR85","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"9946_CR86","doi-asserted-by":"crossref","unstructured":"Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001:2282\u201392.","DOI":"10.1200\/JCO.2001.19.8.2282"},{"key":"9946_CR87","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1200\/JCO.2002.10.129","volume":"20","author":"J Carmichael","year":"2002","unstructured":"Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur\/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20:3617\u201327.","journal-title":"J Clin Oncol"},{"issue":"17","key":"9946_CR88","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2002.04.123","volume":"20","author":"JY Douillard","year":"2002","unstructured":"Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil\/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20(17):3605\u201316.","journal-title":"J Clin Oncol"},{"key":"9946_CR89","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A De Gramont","year":"2000","unstructured":"De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938\u201347.","journal-title":"J Clin Oncol"},{"key":"9946_CR90","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metstatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041\u20137.","journal-title":"Lancet"},{"key":"9946_CR91","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","volume":"25","author":"R Porschen","year":"2007","unstructured":"Porschen R, Arkenau H-T, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007;25:4217\u201323.","journal-title":"J Clin Oncol"},{"key":"9946_CR92","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) as first-line treatment of metastaticcolorectal cancer: the GruppoOncologico Nord Ovest. J Clin Oncol. 2007;25:1670\u20136.","journal-title":"J Clin Oncol"},{"issue":"9","key":"9946_CR93","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/oxfordjournals.annonc.a010800","volume":"7","author":"D Cunningham","year":"1996","unstructured":"Cunningham D. Zalcberg Jr, Rath U, et al. final results of a randomised trial comparing tomudex (raltitrexed) with 4-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. Ann Oncol. 1996;7(9):961\u20135.","journal-title":"Ann Oncol"},{"issue":"9","key":"9946_CR94","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","volume":"16","author":"G Cocconi","year":"1998","unstructured":"Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus hig-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal Cancer Study Group. J Clin Oncol. 1998;16(9):2943\u201352.","journal-title":"J Clin Oncol"},{"key":"9946_CR95","unstructured":"Pazdur R, Vincent M. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (%-FU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Paper presented at ASCO Meeting Abstract: Denver, USA: 1997"},{"issue":"8","key":"9946_CR96","first-page":"606","volume":"14","author":"C Gravalos","year":"2012","unstructured":"Gravalos C, Salut A, Garcia-Giron C, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. ClinTransl Oncol. 2012;14(8):606\u201312.","journal-title":"ClinTransl Oncol"},{"issue":"15","key":"9946_CR97","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/jco.2011.29.15_suppl.3562","volume":"29","author":"H Baba","year":"2011","unstructured":"Baba H, Muro K, Yasui H, et al. Updated results of the FIRIS study: a phase II\/III trial of 5-FU\/leucovorin\/irinotecan (FOLFIRI) versus irinotecan\/S-1 (IRIS) as second-line chemotherapy for metastastic colorectal c\u00e1ncer (mCRC). J Clin Oncol. 2011;29(15):3562.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9946_CR98","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/jco.2012.30.4_suppl.586","volume":"30","author":"T Otsuji","year":"2012","unstructured":"Otsuji T, Yamazaki K, Ojima H, et al. Updated survival of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastastic colorectal cancer (mCRC). J Clin Oncol. 2012;30(4):586.","journal-title":"J Clin Oncol"},{"key":"9946_CR99","first-page":"883","volume":"14","author":"ST Kim","year":"2014","unstructured":"Kim ST, Hong YS, Lim HY, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC. 2014;14:883.","journal-title":"BMC"},{"key":"9946_CR100","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"9946_CR101","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715\u201321.","journal-title":"J Clin Oncol"},{"key":"9946_CR102","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","volume":"27","author":"M Stahl","year":"2009","unstructured":"Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851\u20136.","journal-title":"J Clin Oncol"},{"key":"9946_CR103","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","volume":"18","author":"WF Regine","year":"2011","unstructured":"Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18:1319\u201326.","journal-title":"Ann Surg Oncol"},{"key":"9946_CR104","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"204","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;204:1073\u201381.","journal-title":"JAMA"},{"key":"9946_CR105","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization of Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040\u20139.","journal-title":"J Clin Oncol"},{"key":"9946_CR106","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","volume":"102","author":"J Northover","year":"2010","unstructured":"Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT-I). Br J Cancer. 2010;102:1123\u20138.","journal-title":"Br J Cancer"},{"key":"9946_CR107","doi-asserted-by":"publisher","first-page":"1726.1733","DOI":"10.1038\/bjc.2014.467","volume":"111","author":"D Meulendijks","year":"2014","unstructured":"Meulendijks D, Dewit L, Tomasoa NB, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer. 2014;111:1726.1733.","journal-title":"Br J Cancer"},{"key":"9946_CR108","doi-asserted-by":"crossref","unstructured":"Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2009:CD006041","DOI":"10.1002\/14651858.CD006041.pub2"},{"key":"9946_CR109","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13:579\u201388.","journal-title":"Lancet Oncol."},{"key":"9946_CR110","doi-asserted-by":"crossref","unstructured":"O\u2019Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial T-04. J Clin Oncol. 2014;32:1927\u201334.","DOI":"10.1200\/JCO.2013.53.7753"},{"key":"9946_CR111","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-93-4-533","volume":"93","author":"JS MacDonald","year":"1980","unstructured":"MacDonald JS, Schein PS, Woolley PV, et al. 5-fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Inern Med. 1980;93:533\u20136.","journal-title":"Ann Inern Med"},{"key":"9946_CR112","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1200\/JCO.1997.15.1.261","volume":"15","author":"A Webb","year":"1997","unstructured":"Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261\u20137.","journal-title":"J Clin Oncol"},{"key":"9946_CR113","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36\u201346.","journal-title":"N Engl J Med"},{"key":"9946_CR114","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang YK, Kang WK, Shin DB, et al. Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666\u201373.","journal-title":"Ann Oncol"},{"key":"9946_CR115","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"9946_CR116","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547\u201353.","journal-title":"J Clin Oncol"},{"key":"9946_CR117","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","volume":"20","author":"JD Berlin","year":"2002","unstructured":"Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastrern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270\u20135.","journal-title":"J Clin Oncol"},{"key":"9946_CR118","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","volume":"25","author":"R Hermann","year":"2007","unstructured":"Hermann R, Bodoky G, Rushtaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212\u20137.","journal-title":"J Clin Oncol"},{"key":"9946_CR119","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-017-9946-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-017-9946-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-017-9946-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:37:12Z","timestamp":1628599032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-017-9946-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,10]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["9946"],"URL":"https:\/\/doi.org\/10.1007\/s12029-017-9946-5","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,10]]},"assertion":[{"value":"10 April 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}